TP53 and Miyoshi myopathy: While malignant plasma cells (PCs) usually present key genomic features of active MM (including chromosomal aberrations such as translocations involving IgH or hyperdiploidy/TP53 mutations/MYC translocations) [9], only 1% MGUS and 10% sMM per year eventually evolve to overt MM, supporting the idea that “cell-intrinsic” factors (i.e., genomic alterations) are not sufficient, alone, for disease evolution.